Monday, 29 May 2023

#Enzyme #Bromelain Inhibits the Symptoms of #FunctionalDyspepsia Cuased by Helicobacter Pylori Infection, According to Studies

By Kyle J. Norton

Functional dyspepsia, also known as indigestion, is a symptom in the stomach associated with difficulty in digesting food.

The most common symptoms of indigestion are pain or discomfort in your upper abdomen (dyspepsia) or burning pain behind the breastbone (heartburn) soon after eating.

Some patients may also experience symptoms of feeling full or bloated with no signs of relief.


In serious cases, patients may also experience symptoms of vomiting blood, dark, tarry stools due to damage to the lining of the stomach, shortness of breath, and unexplained weight loss.

If you have some of the aforementioned symptoms, please check with the doctor immediately


There exact causes of indigestion are multiple. Epidemiologically, female gender, aging, long-term use of pain relievers, such as aspirin and ibuprofen, smoking, and people with long-term psychological problems such as anxiety or depression are some most common factors found in patients with functional dyspepsia.

Conventionally, treatment of functional dyspepsia is totally depending on the condition, including antibiotics for H. pylori infection and medication to reduce pain.

Bromelain, a proteolytic enzyme found in pineapples (Ananas comosus) has been used in traditional medicine as an inflammatory agent and to treat pains, strains, and muscle aches and pains and ease back pain and chronic joint pain, skin diseases, etc.

In finding potential and natural compounds for the treatment of functional dyspepsia, researchers examined a dietary integrator composed of sodium alginate, sodium bicarbonate, bromelin, and essential oils in patients affected by functional dyspepsia.

The study included a study of a total of 100 patients with functional dyspepsia diagnosed primarily on the basis of typical symptoms and the exclusion of non-functional gastrointestinal diseases.

According to the symptom classification, All patients were assigned to either dysmotility-like dyspepsia (N.=60) or reflux-like dyspepsia (N.=40).

All patients were treated with TUBES Gastro (0.80 g oral tablets bid after main meals) for 4 weeks, on top of their current treatment with proton pump inhibitors or not.


According to the results from the experiment, TUBES Gastro showed a high statistically significant reduction of the Numerical Rating Scale (NRS) scores at 14 and 28 days: -1.5 (-26.3%) and -3.4 (-59.6%), respectively compared to the baseline in patients with dysmotility-like dyspepsia.

In patients with reflux-like dyspepsia, TUBES Gastro demonstrated a statistically significant reduction of the NRS score at 14 and 28 days: -2.8 (-41.2%) and -4.8 (70.6%), respectively (P<0.0001).

Furthermore, there were no side effects found during the study duration.


Based on the findings, researchers wrote, "TUBES Gastro treatment was effective and well-tolerated in reducing the symptomatology of patients affected by functional dysmotility-like and reflux-like dyspepsia".

In order to reveal additional information of TUBES Gastro anti-functional dyspepsia, researchers at the Molinette Hospital conducted a study to examine the preparation efficacy on a total of 53 consecutive patients (22 males, 31 females; mean age, 54+/-2.5 years) with functional dyspepsia and negative for Helicobacter pylori infection.

Patients classified to four subgroups according to predominant symptom: ulcer-like dyspepsia, Motility-like dyspepsia, reflux-like dyspepsia, and nonspecific dyspepsia, were received TUBES gastro (0.80 g oral tablets bid) for a minimum of 3 months (range, 3-11).

According to the results of patients who completed the study, the preparation showed a strong effect on the improvement in Visual Analogue Scale (VAS). score.

Compared to the based line, the difference in scores between the initial and the final visit was -1.9+/-2.1 cm (range, -6 to +3), or 23.8+/-40.8% (range, -150% to 100%).

Dr. Pellicano R, the lead scientist wrote, "The study results indicate that in the short term TUBES, gastro can significantly improve dyspeptic symptoms in dyspeptic patients negative for H. pylori infection".

Taken altogether, bromelain used alone or combined with other remedies may be considered supplements for the prevention and treatment of functional dyspepsia, pending the confirmation of the larger sample size and multicenter human study.


Intake of bromelain in the form of supplements should be taken with extreme care to prevent overdose acute liver toxicity.

Natural Medicine for Fatty Liver And Obesity Reversal - The Revolutionary Findings To Achieve Optimal Health And Lose Weight

How To Get Rid Of Eye Floaters
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months

Back to Kyle J. Norton's Homepage http://kylejnorton.blogspot.ca



Author Biography
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the Karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as the international journal Pharma and Bioscience, ISSN 0975-6299.

Sources
(1) Can dietary integrators provide a clinical benefit in the treatment of functional dyspepsia? results from a prospective study with TUBES Gastro by Molteni M. (PubMed)
(2) Benefit of dietary integrators for treating functional dyspepsia: a prospective pilot study.[Article in English, Italian] by Pellicano R1, Strona S, Simondi D, Reggiani S, Pallavicino F, Sguazzini C, Bonagura AG, Rizzetto M, Astegiano M. (PubMed)

No comments:

Post a Comment